[go: up one dir, main page]

WO2001096564A3 - Isoforme d'hla-g (hla-g7) et ses applications - Google Patents

Isoforme d'hla-g (hla-g7) et ses applications Download PDF

Info

Publication number
WO2001096564A3
WO2001096564A3 PCT/FR2001/001827 FR0101827W WO0196564A3 WO 2001096564 A3 WO2001096564 A3 WO 2001096564A3 FR 0101827 W FR0101827 W FR 0101827W WO 0196564 A3 WO0196564 A3 WO 0196564A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
isoform
applications
risks
immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2001/001827
Other languages
English (en)
Other versions
WO2001096564A2 (fr
Inventor
Edgardo Delfino Carosella
Pascale Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Publication of WO2001096564A2 publication Critical patent/WO2001096564A2/fr
Publication of WO2001096564A3 publication Critical patent/WO2001096564A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouvelle isoforme d'HLA-G soluble (HLA-G7) et ses applications, liées à ses propriétés immunomodulatrices, pour le diagnostic des maladies autoimmunes et des risques d'avortement à répétition et le traitement, chez l'homme de troubles liés à l'immunité.
PCT/FR2001/001827 2000-06-13 2001-06-13 Isoforme d'hla-g (hla-g7) et ses applications Ceased WO2001096564A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007529A FR2810047B1 (fr) 2000-06-13 2000-06-13 Nouvelle isoforme d'hla-g et ses applications
FR00/07529 2000-06-13

Publications (2)

Publication Number Publication Date
WO2001096564A2 WO2001096564A2 (fr) 2001-12-20
WO2001096564A3 true WO2001096564A3 (fr) 2002-03-14

Family

ID=8851220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/001827 Ceased WO2001096564A2 (fr) 2000-06-13 2001-06-13 Isoforme d'hla-g (hla-g7) et ses applications

Country Status (2)

Country Link
FR (1) FR2810047B1 (fr)
WO (1) WO2001096564A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287556A1 (en) * 2004-05-06 2005-12-29 Carole Ober Use of HLA-G genotyping in immune-mediated conditions
WO2007011044A1 (fr) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation Composition pharmaceutique comprenant un dimere hla-g lie disulfide et procede de fabrication de ce dimere hla-g lie disulfide
FR2934498B1 (fr) * 2008-08-01 2014-08-15 Commissariat Energie Atomique Utilisation d'une forme soluble d'hla-g dans le traitement des proliferations anormales des lymphocytes b.
EP2184070A1 (fr) 2008-11-07 2010-05-12 Hla-G Technologies Protéines HLA-G et leurs utilisations pharmaceutiques
EA201200028A1 (ru) * 2009-06-18 2012-06-29 Хла-Ж Текнолоджиз Альфа-1 мультимеры hla-g и их фармацевтическое применение
EP2264067A1 (fr) 2009-06-18 2010-12-22 Hla-G Technologies Multimères de HLA-G alpha 1 et leurs utilisations pharmaceutiques
JP5802661B2 (ja) 2009-06-25 2015-10-28 コミッサリア ア レネルジ アトミック エ オー エネルジ アルターネイティブスＣｏｍｍｉｓｓａｒｉａｔ Ａ Ｌ’Ｅｎｅｒｇｉｅ Ａｔｏｍｉｑｕｅ Ｅｔ Ａｕｘ Ｅｎｅｒｇｉｅｓ Ａｌｔｅｒｎａｔｉｖｅｓ α１−α３単量体を含むＨＬＡ−Ｇの多量体ポリペプチド及び医薬としてのその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (fr) * 1995-04-07 1996-10-10 The Regents Of The University Of California Anticorps pour la detection de hla-g
WO1998037098A1 (fr) * 1997-02-21 1998-08-27 Commissariat A L'energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications
WO1999042128A1 (fr) * 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
WO1999043851A1 (fr) * 1998-02-25 1999-09-02 National University Of Ireland, Cork Gene de susceptibilite a la pre-eclampsie et aux fausses-couches lie au hla
WO2000078337A1 (fr) * 1999-06-18 2000-12-28 Commissariat A L'energie Atomique Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (fr) * 1995-04-07 1996-10-10 The Regents Of The University Of California Anticorps pour la detection de hla-g
WO1998037098A1 (fr) * 1997-02-21 1998-08-27 Commissariat A L'energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications
WO1999042128A1 (fr) * 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
WO1999043851A1 (fr) * 1998-02-25 1999-09-02 National University Of Ireland, Cork Gene de susceptibilite a la pre-eclampsie et aux fausses-couches lie au hla
WO2000078337A1 (fr) * 1999-06-18 2000-12-28 Commissariat A L'energie Atomique Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CAROSELLA, E.D. ET AL.: "HLA-G and HLA-E: fundamental and pathophysiological aspects", IMMUNOLOGY TODAY, vol. 21, no. 11, November 2000 (2000-11-01), pages 532 - 534, XP004221156 *
DATABASE EMBL 1 January 1900 (1900-01-01), ISHITANI A., GERAGHTY D. E.: "HUMAN LYMPHOCYTE ANTIGEN (HLA-G1) MRNA, COMPLETE CDS.", XP002162349, Database accession no. M90683 *
DATABASE EMBL 1 January 1900 (1900-01-01), YAMASHITA T.: "HOMO SAPIENS DNA FOR HLA-G, EXON 2.", XP002162350, Database accession no. D85032 *
DATABASE MEDLINE [online] 1999, KOMATSU, F. & YOSHIDA, S.: "Characteristics of human T-lymphotropic virus type-1 (HTLV-1)-infected cell line MT-2, which is not killed by a natural killer cell line NK-92 but is killed by lymphokine-activated killer cells", XP002185653, Database accession no. 2000074327 *
ISHITANI, A. & GERAGHTY, D.E.: "Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, no. 9, 1 May 1992 (1992-05-01), pages 3947 - 3951, XP002007028 *
ONNO, M. ET AL.: "Modulation of HLA-G Antigens Expression by Human Cytomegalovirus: Specific Induction in Activated Macrophages Harboring Human Cytomegalovirus Infection", JOURNAL OF IMMUNOLOGY, vol. 164, no. 12, 15 June 2000 (2000-06-15), pages 6426 - 6434, XP002185652 *
PAUL, P. ET AL.: "Identification of HLA-G7 as a New Splice Variant of the HLA-G mRNA and Expression of Soluble HLA-G5, -G6, and -G7 Transcripts in Human Transfected Cells", HUMAN IMMUNOLOGY, vol. 61, no. 11, November 2000 (2000-11-01), pages 1138 - 1149, XP000926217 *
ROUAS-FREIS, N. ET AL.: "The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: Is HLA-G the public ligand for natural killer cell inhibitory receptors?", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, no. 10, 13 May 1997 (1997-05-13), pages 5249 - 5254, XP002046238 *
ROUAS-FREISS, N. ET AL.: "HLA-G promotes immune tolerance", JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, vol. 14, no. 2, April 2000 (2000-04-01), pages 93 - 98, XP000926216 *
YEE, C. ET AL.: "Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Polpulations Using Peptide-MHC Tetramers", JOURNAL OF IMMUNOLOGY, vol. 162, no. 4, 15 February 1999 (1999-02-15), pages 2227 - 2234, XP002156019 *

Also Published As

Publication number Publication date
FR2810047B1 (fr) 2004-04-02
FR2810047A1 (fr) 2001-12-14
WO2001096564A2 (fr) 2001-12-20

Similar Documents

Publication Publication Date Title
WO2003057134A3 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
AU2001228759A1 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
WO2001089457A3 (fr) Mimiques de thrombopoietine
EP1018517A3 (fr) Agents liants au CD23 pour le traitement des maladies inflammatoires, autoimmunes ou allergiques
AU2002357643A1 (en) The human mob-5 (il-24) receptors and uses thereof
ZA9710098B (en) Halogenopyrimidines.
WO2002100442A3 (fr) Utilisation de l-polynucleotides et de leurs derives
AUPR301001A0 (en) Compression garments and methods of use
AU2002240463A1 (en) Use of endostatin in the treatment of ocular neovascularization
WO2001096564A3 (fr) Isoforme d'hla-g (hla-g7) et ses applications
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU2002362505A1 (en) Compression sleeve for treatment of the extremities
WO2003050137A3 (fr) Mutations de recepteur de type toll 4
WO2005002617A3 (fr) Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2002043745A3 (fr) Histaminase d'origine vegetale utilisee pour traiter des chocs allergiques et septiques et l'asthme allergique
MXPA04001976A (es) Hormona de crecimiento humano modificada.
WO2005011728A3 (fr) Utilisation de cd164 soluble pour les troubles inflammatoires ou auto-immuns
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
AU2000243264A1 (en) Human nim1 kinase
WO2002040514A3 (fr) Voie de secretion de type iii chez aeromonas salmonicida, et utilisations correspondantes
AU6871501A (en) Cgi-69 compositions and methods of use
WO2001066740A3 (fr) Compositions et methodes de traitement de maladies d'origine immune
WO2002074330A3 (fr) Agent d'immunotherapie
WO2001078765A3 (fr) Prophylaxie et traitement du diabete insulino-dependant de type 1 a l'aide d'enzymes proteolytiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA IL JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA IL JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP